Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy.

about

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence

P2860

Q57107345-F0129A7E-9179-4B88-947F-A1F9A64CCD1B

P2860

Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy.

Item

http://www.wikidata.org/entity/Q52739363

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Fulvestrant: A Review in Advan ...... reated with Endocrine Therapy.

@en

Fulvestrant: A Review in Advan ...... reated with Endocrine Therapy.

@nl

type

Item

label

Fulvestrant: A Review in Advan ...... reated with Endocrine Therapy.

@en

Fulvestrant: A Review in Advan ...... reated with Endocrine Therapy.

@nl

prefLabel

Fulvestrant: A Review in Advan ...... reated with Endocrine Therapy.

@en

Fulvestrant: A Review in Advan ...... reated with Endocrine Therapy.

@nl

P1476

Fulvestrant: A Review in Advan ...... reated with Endocrine Therapy.

@en

P2093

Emma D Deeks

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2012

Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant

Fulvestrant in advanced breast cancer: evidence to date and place in therapy.

Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.

Postmenopausal Breast Cancer, Aromatase Inhibitors, and Bone Health: What the Surgeon Should Know.

P2888

s40265-017-0855-5

P304

131-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S40265-017-0855-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29270913

http://www.w3.org/2001/XMLSchema#string

Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy.

about

P2860

P2860

Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698